A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis. Celldex_CDX0159-08_Pro00112764
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 23, 2023
End Date
February 28, 2026
Administered By
Medicine, Gastroenterology
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 23, 2023
End Date
February 28, 2026